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Abbreviations 
 
CDCA3: cell division cycle associated 3 
CDK4: cyclin-dependent kinase 4 
CDK6: cyclin-dependent kinase 6 
CDKI: cyclin-dependent kinase inhibitor 
DMEM: Dulbecco’s modified Eagle medium 
FBS: fetal bovine serum 
GAPDH: glyceraldehyde-3-phosphate dehydrogenase 
HNOK: human normal oral keratinocyte 
IHC: immunohistochemistry 
OPL: oral premalignant lesion 
OSCC: oral squamous cell carcinoma 
PBS: phosphate buffered saline 
qRT-PCR: quantitative reverse transcriptase-polymerase chain reaction 
RING: really interesting new gene 
ROC1: RING domain containing protein regulator of cullins-1 
SCF: Skp1-cullin-F-box 
SD: standard deviation 
SEM: standard error of the mean 
shRNA: small hairpin RNA 
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Abstract 
 
Background: Cell division cycle associated 3 (CDCA3), part of the 
Skp1-cullin-F-box (SCF) ubiquitin ligase, refers to a trigger of mitotic entry 
and mediates destruction of the mitosis inhibitory kinase. Little is known 
about the relevance of CDCA3 to human malignancy including oral squamous 
cell carcinoma (OSCC). We aimed to characterize the expression state and 
function of CDCA3 in OSCC. 
Methods: We evaluated CDCA3 mRNA and protein expression in both 
OSCC-derived cell lines and primary OSCCs and performed functional 
analyses of CDCA3 in OSCC-derived cells using the shRNA system.  
Results: The CDCA3 expression at both the mRNA and protein levels was 
frequently up-regulated in all cell lines examined and primary tumors (mRNA, 
51/69, 74%; protein, 79/95, 83%) compared to normal controls (p < 0.001). In 
contrast, no significant level of CDCA3 protein expression was seen in oral 
premalignant lesions (OPLs) (n=20) compared with the expression in OSCCs. 
Among the clinical variables analyzed, the CDCA3 expression status was 
closely related to tumor size (p < 0.05). In addition, suppression of CDCA3 
expression with shRNA significantly (p < 0.05) inhibited cellular proliferation 
compared with the control cells by arresting cell-cycle progression at the G1 
phase. Further, there was up-regulation of the cyclin-dependent kinase 
inhibitors (p21Cip1, p27Kip1, p15INK4B, and p16INK4A) in the knockdown cells. 
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Conclusion: The current results showed that overexpression of CDCA3 
occurs frequently during oral carcinogenesis and this overexpression might be 
associated closely with progression of OSCCs by preventing the arrest of 
cell-cycle progression at the G1 phase via decreased expression of the 
cyclin-dependent kinase inhibitors.  
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Background 
 
Rapid cellular growth and division are common features in all malignant cells 
including oral squamous carcinoma [1]. It is well documented that 
inappropriate expression of cell-cycle regulatory proteins can contribute to 
human tumorigenesis [2]. Numerous studies have reported the relation 
between carcinogenesis and the cell-cycle-related gene [3-6]. In particular, 
recent studies have suggested that deregulation of Skp1-cullin-F-box (SCF) 
control of the G1/S phase targets also might contribute to human 
tumorigenesis [3,7-9]. 
Our previous microarray analysis showed that CDCA3, referred to as a 
trigger of mitotic entry, mediates destruction of mitosis and the inhibitory 
kinase via the E3 ligase, SCF [10-14] and was one of the up-regulated genes in 
the oral squamous cell carcinoma (OSCC)-derived cells [15]. The 
ubiquitin-proteasome system is one of the critical mechanisms controlling 
protein turnover and thus maintains cellular protein homeostasis [16]. 
Although protein ubiquitination is catalyzed by a highly ordered enzymatic 
cascade, including ubiquitin-activating enzyme E1s, ubiquitin-conjugating 
enzyme E2s, and ubiquitin ligase E3s, the last of which primarily determine 
the substrate specificity [16,17]. The SCF, E3 ubiquitin ligases, consisting of 
Skp1, cullins/cdc53, F-box proteins, and the RING domain containing protein 
regulator of cullins-1 (ROC1)/ring box protein-1, are crucial to the regulation of 
numerous cellular processes under both physiologic and pathologic conditions 
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as part of the ubiquitin-proteosome system [18]. By promoting degradation of 
many short-lived proteins, including cell cycle regulators, transcription factors 
and signal transducers, SCF E3 ligases regulate many biological processes [19]. 
CDCA3 is a protein that contains an F box motif and bind to Skp1 and cullin, a 
component of SCF. Since the F-box protein determines the specificity of SCF 
ligases, it represents a target that could provide the greatest potential 
selectivity [20]. As a critical cell-cycle regulator, p27 Kip1 arrests cell division 
and inhibits G1/S transition, and the cellular p27Kip1 levels are modulated 
largely through the ubiquitin-proteasome pathway [21]. Thus, progression of 
the cell cycle can be regulated by modulating the quantities of cell-cycle 
regulators through ubiquitination by the SCF complex [1]. However, the 
expression state and function of CDCA3 in OSCCs are not fully characterized.  
The current study shows the results of a comprehensive analysis of 
aberrant expression of CDCA3 in OSCCs that are clinically and functionally 
linked to tumor progression. 
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Materials & Methods 
 
Cell culture  
HSC-2, HSC-3, HSC-4, and Ca9-22 cell lines, derived from human OSCCs, 
were purchased from the Human Science Research Resources Bank, Osaka, 
Japan. H1 and Sa3 were kindly provided by Dr. S. Fujita of Wakayama 
Medical University, Wakayama, Japan. HNOKs were used as a normal control 
[22,23]. All cells were grown in Dulbecco’s modified Eagle medium (DMEM) 
F-12 HAM (Sigma Aldrich, St. Louis, MO) supplemented with 10% fetal bovine 
serum (FBS) (Sigma) and 50 units/ml penicillin and streptomycin (Sigma). 
 
Tissue specimens 
Primary OSCC samples and corresponding normal oral epithelial tissues were 
obtained at the time of surgeries performed at Chiba University Hospital. All 
patients provided informed consent for the study protocol, which was approved 
by the institutional review board of Chiba University. The tissues were divided 
into two parts, one of which was frozen immediately and stored at -80°C until 
RNA isolation, and the second was fixed in 20% buffered formaldehyde solution 
for pathologic diagnosis and IHC. The Department of Pathology, Chiba 
University Hospital, performed the histopathologic diagnosis of each tissue 
according to the World Health Organization criteria. Clinicopathological 
staging was determined according to the tumor-node-metastases classification 
of the International Union against Cancer. All OSCC samples were confirmed 
histologically and checked to ensure the presence of tumor in greater than 90% 
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of specimens. 
  
Preparation of cDNA 
Total RNA was isolated using Trizol Reagent (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s instructions. cDNA was generated from 5 µg of 
total RNA using Ready-To-Go You-Prime First-Strand Beads (GE Healthcare, 
Buckinghamshire, UK) and oligo (dT) primer (Sigma Genosys, Ishikari, Japan), 
according to the manufacturer’s instructions. 
 
mRNA expression analysis 
qRT-PCR was performed to evaluate the expression levels of CDCA3 and Wee1 
mRNA in OSCC-derived cell lines and HNOKs. We also evaluated the mRNA 
levels in primary OSCCs and paired specimens of normal oral tissues obtained 
from 69 patients. qRT-PCR was performed using LightCycler 480 apparatus 
(Roche Diagnostics GmbH, Mannheim, Germany). Primers were designed 
using the ProbeFinder qPCR assay design software, which is freely accessible 
at www.universalprobelibrary.com. The sequences of the gene-specific primers 
were as follows: CDCA3 forward 5’-TGGTATTGCACGGACACCTA-3’ and 
reverse 5’-TGTTTCACCAGTGGGCTTG-3’; Wee1 forward 
5’-TTTGGTTCACATGGATATAAAACCT-3’ and reverse 
5’-CCCAATCATCTTCGTCTCCT-3’. The PCR reactions were carried out in a 
final volume of 20 µl of a reaction mixture comprised of 10 µl of LightCycler 
480 Probes Master (Roche), 0.2 µl of universal probe (Roche), and 4 µM of the 
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primers, according to the manufacturer’s instructions. The reaction mixture 
was loaded onto the PCR plate and subjected to an initial denaturation at 95°C 
for 10 min, followed by 45 rounds of amplification at 95°C (10 sec) for 
denaturation, 60°C (30 sec) for annealing, and 72°C (1 sec) for extension, 
followed by a cooling step at 50°C for 30 seconds. The transcript amounts for 
the CDCA3 and Wee1 genes were estimated from the respective standard 
curves and normalized to the glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) forward 5’-AGCCACATCGCTCAGACAC-3’ and reverse 
5’-GCCCAATACGACCAAATCC-3’ transcript amount determined in 
corresponding samples.  
 
Protein expression analysis  
The cells were washed twice with cold phosphate buffered saline (PBS) and 
centrifuged briefly. The cell pellets were incubated at 4°C for 30 min in a lysis 
buffer (7 M urea, 2 M thiourea, 4% w/v CHAPS, and 10 mM Tris pH 7.4) with a 
proteinase inhibitor cocktail (Roche). The protein concentration was measured 
using the Bradford reagent (Bio-Rad, Richmond, CA). Protein extracts were 
electrophoresed on 4% to 12% Bis-Tris gel, transferred to nitrocellulose 
membranes (Invitrogen), and blocked for 1 hr at room temperature with 
Blocking One (Nacalai Tesque, Inc., Kyoto, Japan). The membranes were 
washed three times with 0.1% Tween-20 in Tris-buffered saline and incubated 
with antibody for CDCA3 (Abcam, Cambridge, UK), p21Cip1, p27Kip1, p15INK4B, 
p16INK4A, CDK4, CDK6, Cyclin D1 (Cell Signaling Technology, Danvers, MA), 
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and Cyclin E (Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C and 
α-tubulin (Santa Cruz Biotechnology) 1 hr at room temperature. The 
membranes were washed again and incubated with a anti-rabbit or anti-mouse 
IgG (H+L) horseradish peroxidase conjugate (Promega, Madison, WI) as a 
secondary antibody for 1 hr at room temperature. Finally, the membranes were 
detected using SuperSignal West Pico Chemiluminescent substrate (Thermo, 
Rockford, IL), and immunoblotting was visualized by exposing the membranes 
to ATTO Light-Capture II (Tokyo, Japan). Signal intensities were quantitated 
using the CS Analyzer version 3.0 software (ATTO). 
 
IHC 
IHC of 4 µm sections of paraffin-embedded specimens was performed using 
rabbit anti-CDCA3 polyclonal antibody (Abcam). Briefly, after 
deparaffinization and hydration, the endogeneous peroxidase activity was 
quenched by a 30 min incubation in a mixture of 0.3% hydrogen peroxide 
solution in 100% methanol, after which the sections were blocked for 2 hr at 
room temperature with 1.5% blocking serum (Santa Cruz Biotechnology) in 
PBS before reaction overnight with anti-CDCA3 antibody (1:100 dilution) at 
4°C in a moist chamber. Upon incubation with the primary antibody, the 
specimens were washed three times in PBS and treated with Envision reagent 
(DAKO, Carpinteria, CA) followed by color development in 
3,3’-diaminobenzidine tetrahydrochloride (DAKO). The slides then were lightly 
counterstained with hematoxylin, dehydrated with ethanol, cleaned with 
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xylene, and mounted. Non-specific binding of an antibody to proteins other 
than the antigen sometimes occurred. To avoid non-specific binding, an 
immunizing peptide blocking experiment was performed. As a negative control, 
triplicate sections were immunostained without exposure to primary antibodies, 
which confirmed the staining specificity. To quantify the status of the CDCA3 
protein expression in those components, we used an IHC scoring system 
described previously [22-26]. This IHC scoring system was established for 
quantitative evaluation of IHC staining. The stained cells were determined in 
at least five random fields at 400 × magnification in each section. We counted 
300 cells per one field of vision. The staining intensity (1, weak; 2, moderate; 3, 
intense) and the number of positive cells in the field of vision then were 
multiplied to calculate the IHC score using the following formula: IHC score = 
1 × (number of weakly stained cells in the field) + 2 × (number of moderately 
stained cells in the field) + 3 × (number of intensely stained cells in the field). 
Cases with a CDCA3 IHC score exceeding 94.7 (maximum score within + 3 
standard deviation (SD) of the mean of normal tissues) were defined as 
CDCA3-positive because 100% of the distribution falls within ± 3 SD of the 
mean in normal tissues. Two independent pathologists, both masked to the 
patients’ clinical status, made these judgments. 
 
Stable transfection of CDCA3 shRNA 
Stable transfection was performed at about 80% confluency in 24 well plates 
using Lipofectamine LTX and Plus Reagents (Invitrogen), according to the 
manufacturer’s instructions. Briefly, a total of 2 × 105 cells were seeded into 
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each well in DMEM F-12 HAM (Sigma) containing 10% FBS (Sigma) without 
antibiotics. shCDCA3 and mock (0.1 µg) (Santa Cruz Biotechnology) vectors 
were transfected into OSCC-derived cells (H1 and Sa3) with 0.5 µl of Plus 
Reagents and 1.25 µl of Lipofectamine LTX. After transfection, the cells were 
isolated by the culture medium containing 2 µg/mL puromycin (Invitrogen). 
After 3 to 4 weeks, resistant cell clones were picked and transferred to 6-well 
plates and gradually expanded to 10-cm dishes. At 90% confluence, qRT-PCR 
and Western blot analyses were performed to assess the efficiency of CDCA3 
knockdown.  
 
Cellular growth 
To evaluate the effect of CDCA3 knockdown on cellular proliferation, we 
analyzed cellular growth in shCDCA3- and mock-transfected cells. These 
transfectants were seeded in 6-well plates at a density of 1 × 104 viable cells 
per well. The experiments were carried out for 168 hr, and the cells were 
counted every 24 hr. At the indicated time point, the cells were trypsinized and 
counted using a hemocytometer in triplicate samples. 
 
Cell-cycle analysis 
To assess cell-cycle distribution of entire cell populations, the cells were 
harvested, washed with PBS, and probed with CycleTEST Plus DNA reagent 
kit (Becton-Dickinson, San Jose, CA), according to the manufacturer’s protocol. 
Briefly, the cells were centrifuged at 400 × g for 5 min. The cell pellets were 
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resuspended with 250 µl of trypsin buffer, and incubated for 10 min at room 
temperature. We then added 200 µl of trypsin inhibitor and RNase buffer. 
Finally, the cells were labeled with 200 µl of propidium iodide stain solution. 
Flow cytometric determination of DNA content was analyzed by FACSCalibur 
(Becton-Dickinson). The fractions of the cells in the G0-G1, S, and G2-M phases 
were analyzed using Flow Jo software (Tree Star, Ashland, OR). 
 
Statistical analysis 
Statistical significance was determined using Fisher’s exact test or the 
Mann-Whitney’s U test. p < 0.05 was considered significant. The data are 
expressed as the mean ± standard error of the mean (SEM). 
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Results 
 
Evaluation of CDCA3 expression in OSCC-derived cell lines 
and primary OSCCs 
To investigate mRNA and protein expression of CDCA3 identified as a 
cancer-related gene in our previous microarray data [15], we performed 
real-time quantitative reverse transcriptase-polymerase chain reaction 
(qRT-PCR) and Western blot analyses using six OSCC-derived cell lines 
(HSC-2, HSC-3, HSC-4, Ca9-22, H1, and Sa3) and primary cultured human 
normal oral keratinocytes (HNOKs). CDCA3 mRNA was significantly (*p < 
0.05) up-regulated in all OSCC-derived cell lines compared with the HNOKs 
(Figure 1A). Figure 1B shows representative results of Western blot analysis. 
The molecular weight of CDCA3 was 29 kDa. A significant increase in CDCA3 
protein expression was seen in all OSCC-derived cell lines compared with the 
HNOKs. Expression analysis indicated that both transcription and translation 
products of this molecule were highly expressed in OSCC-derived cell lines. We 
then measured the CDCA3 mRNA expression levels in primary OSCCs and 
paired normal oral tissues from 69 patients (Figure 2A). Similar to the data 
from the OSCC-derived cell lines, qRT-PCR analysis showed that CDCA3 
mRNA expression was up-regulated in 51 (74%) of 69 primary OSCCs 
compared with the matched normal oral tissues. The relative mRNA 
expression levels in the normal oral tissues and primary OSCCs ranged from 
6.3 × 10-5 to 0.442 (median, 0.033) and 5.9 × 10-5 to 1.178 (median, 0.083), 
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respectively. When we analyzed the CDCA3 protein expression in primary 
OSCCs and paired normal oral tissues from 95 patients and oral premalignant 
lesions (OPLs) from 20 patients using the immunohistochemistry (IHC) scoring 
system, the CDCA3 IHC scores in the primary OSCCs, OPLs, and normal oral 
tissues ranged from 2.5 to 225.0 (median, 95.0), 2.5 to 50.0 (median, 15.0), and 
2.5 to 87.5 (median, 22.5), respectively. The CDCA3 IHC score in primary 
OSCCs was significantly (**p < 0.001) higher than those in OPLs and normal 
oral tissues (Figure 2B); there was no significant difference in the IHC scores 
between the OPLs and normal oral tissues. Representative IHC results for 
CDCA3 protein in normal oral tissues, OPLs, and primary OSCCs are shown 
in Figure 2C, D, and E. Strong CDCA3 immunoreactions were detected in the 
cytoplasm in the OSCCs; the OPLs and normal oral tissues showed negative 
immunostaining. CDCA3 protein expression was up-regulated in 79 (83%) of 95 
primary OSCCs compared with the matched normal oral tissues. The 
correlations between the clinicopathologic characteristics of the patients with 
OSCC and the status of the CDCA3 protein expression using the IHC scoring 
system are shown in Table 1. Among the clinical classifications, 
CDCA3-positive OSCCs were correlated significantly (*p < 0.05) with tumor 
size. 
 
Establishment of CDCA3 knockdown cells 
OSCC-derived cells (H1 and Sa3) transfected with CDCA3 shRNA (shCDCA3) 
and the control shRNA (mock) plasmid were cloned. qRT-PCR and Western 
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blot analyses were performed to assess the efficiency of CDCA3 knockdown. 
CDCA3 mRNA expression in shCDCA3-transfected cells was significantly (*p < 
0.05) lower than in mock-transfected cells (Figure 3A and B). CDCA3 protein 
levels in shCDCA3-transfected H1 (Figure 4A) and Sa3 (Figure 4B) cells also 
decreased markedly compared with mock-transfected cells. The densitometric 
CDCA3 protein levels in shCDCA3-transfected cells decreased significantly (*p 
< 0.05) compared with the levels in the mock-transfected cells (Figure 3C and 
D). The CDCA3 protein expression levels were consistent with the mRNA 
levels in the transfectants. 
 
Reduced cellular growth in CDCA3 knockdown cells 
To investigate the antiproliferative effects in shCDCA3-transfected cells, 
cellular growth was monitored for 168 hr. The shCDCA3-transfected H1 
(Figure 4A) and Sa3 (Figure 4B) cells showed a significant decrease in cellular 
growth compared with mock-transfected cells (*p < 0.05). 
 
Knockdown of CDCA3 promotes cell-cycle arrest with cell-cycle 
regulators 
To investigate the mechanism by which down-regulated CDCA3 is related to 
cell-cycle progression, we performed fluorescence-activated cell sorting (FACS) 
analysis of shCDCA3-transfected cells. A representative FACS analysis of 
shCDCA3- and mock-transfected cells is shown in Figure 5A. The percentage of 
the G1 phase in shCDCA3-transfected cells was significantly (*p < 0.05) higher 
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than in mock-transfected cells. To identify the mechanism by which 
down-regulated CDCA3 blocks G1 progression, we assessed the protein 
expression level of cyclin-dependent kinase inhibitors (CDKIs) (p21Cip1, p27Kip1, 
p15 INK4B, p16INK4A), CDK4, CDK6, Cyclin D1, and Cyclin E (Figure 5B, Figure 
6A, and B). The protein expression data showed up-regulation of p21Cip1, 
p27Kip1, p15INK4B, p16INK4A, CDK4, Cyclin D1, and down-regulation of CDK6 
and Cyclin E in the CDCA3 knockdown cells. In addition, to investigate mRNA 
expression of Wee1, a downstream molecule of CDCA3, we performed qRT-PCR 
analysis using six OSCC-derived cell lines (HSC-2, HSC-3, HSC-4, Ca9-22, H1, 
and Sa3) and HNOKs. Wee1 mRNA was significantly (*p < 0.05) 
down-regulated in all OSCC-derived cell lines compared with the HNOKs 
(Figure 7). We also measured Wee1 expression in CDCA3 knockdown cells. The 
qRT-PCR data showed that down-regulation of CDCA3 induced a significant 
(*p < 0.05) increase of Wee1 mRNA levels compared with mock-transfected 
cells (Figure 8A and B). 
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Discussion 
 
Our previous microarray data showed significant up-regulation of CDCA3 in 
OSCC-derived cell lines [15]. The current study also showed for the first time 
significant up-regulation of CDCA3 in OSCC-derived cell lines and primary 
OSCCs compared with the matched normal counterparts. Moreover, CDCA3 
protein expression in OPLs was significantly lower than in OSCCs, whereas no 
significant difference in protein expression was seen between OPLs and normal 
oral tissues. There was no malignant transformation of OPLs after resection. 
Low expression of CDCA3 might prevent undergoing malignant 
transformation of OPLs. In addition, CDCA3 protein expression levels in 
primary OSCCs were correlated with tumor size (Table 1). These findings 
indicated that overexpression of CDCA3 might be linked to human oral 
carcinogenesis and has an important role in OSCC development and 
progression.  
Several cell-cycle regulator proteins are modulated by the SCF complex. 
To activate the SCF complex, Cul1, a component in the SCF complex, is 
conjugated with CDCA3 [10]. However, there has been no direct evidence 
showing that CDCA3 conjugation is required for cell-cycle progression. To 
determine whether CDCA3 function is relevant to OSCC progression, we 
performed the shCDCA3 experiment and found that cellular proliferation 
decreased significantly as a result of cell-cycle arrest at the G1 phase in the 
CDCA3 knockdown cells with up-regulation of p21Cip1, p27Kip1, p15 INK4B, and 
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p16INK4A and down-regulation of CDK6 and Cyclin E. These results were 
consistent with the observations that cell-cycle progression is negatively 
controlled by CDKIs, such as p21Cip1, p27Kip1, p57Kip2, and the INK4 families 
(p15INK4B, p16INK4A, p18INK4C, and p19INK4D), which are involved in cell-cycle 
arrest at the G1 phase and have several functions as tumor suppressor genes 
[7], and that up-regulation of p21Cip1 and/or p27Kip1 causes growth inhibition in 
various cancer models [27-29]. The INK4 families can bind to CDK4 and/or to 
CDK6 and inhibit the catalytic activity of the CDK/Cyclin D complex [30-33]. 
Cyclin D1, Cyclin E, CDK4, and CDK6 are also critical regulators of G1 
progression and G1-S transition [34]. Inhibition of Cyclin D1, Cyclin E, and 
CDK4 activation blocks G1-S transition in the cell cycle [34-37]. Protein 
expression in the INK4 families (p15INK4B and p16INK4A) was up-regulated in 
the CDCA3 knockdown cells, whereas the protein expressions of CDK4 and 
Cyclin D1 were unchanging or increased, suggesting that up-regulation of the 
INK4 families might suppress the CDK4/Cyclin D1 complex activity. Cyclin D1 
is degraded in ubiquitin-proteosome system via the SCF complex. The reason 
why CDK4/CyclinD1 protein expression were increased in the CDCA3 
knockdown cells is considered for inactivation of the SCF complex. We 
therefore speculated that CDCA3 knockdown leads to impaired activation of 
the SCF complex, and consistent with that, we found up-regulation of not only 
the Cip/Kip families (p21Cip1 and p27Kip1) but also the INK4 families (p15INK4B, 
p16INK4A) leading to cell-cycle arrest at the G1 phase in the CDCA3 knockdown 
cells. 
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CDCA3 is associated with Wee1 in a phosphospecific manner, and 
phosphorylation of Wee1 is regulated during the cell cycle [10]. Since Wee1 
inactivates CDK1 and Cyclin B during the S and G2 phases, its activity must 
be down-regulated for mitotic progression to occur [11,38-41]. Wee1 is a key 
player that serves as a mitotic inhibitor in the intricate network of kinases and 
phosphatases that regulate the G2 switchboard [41]. The Wee1 gene has been 
reported to be underexpressed in colon cancer and non-small cell lung cancer 
[36,42]. In the current study, we evaluated Wee1 mRNA expression status in 
OSCC-derived cell lines. Wee1 mRNA was significantly (Figure 7, *p < 0.05) 
down-regulated in all cell lines compared with the control. Wee1 mRNA 
expression then was analyzed in shCDCA3-transfected cells and 
mock-transfected cells. Wee1 expression was significantly (Figure 8A and B, *p 
< 0.05) up-regulated in CDCA3 knockdown cells compared with the control 
cells; however, CDCA3 knockdown cells stop cell-cycle progression at the G1 
phase. These data suggested that G2 arrest was avoided in CDCA3 knockdown 
cells through activation of cdc25, the counterpart of Wee1, which is the switch 
for mitosis. Taken together, it is noteworthy that Wee1 expression originally 
decrease in the H1 and Sa3 cells used for transfection of shCDCA3, indicating 
that CDCA3 plays a role not only during the G2 phase by mediating 
degradation of Wee1 but also the G1 phase by mediating degradation of CDKIs 
in OSCC progression.  
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Conclusion 
 
Our results showed that during oral carcinogenesis overexpression of CDCA3 
occurs frequently and that it might be closely associated with progression of 
OSCCs by preventing cessation of cell-cycle progression at the G1 phase, 
leading to decreased expression of CDKIs. Further studies to identify the 
interaction between CDCA3 and SCF and additional substrates for cell division 
cycle genes and to determine how CDCA3 is dysregulated in various cancers 
and the functional role of CDCA3 during oral carcinogenesis might reveal novel 
mechanisms for cell-cycle regulation. 
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Figure 1 Evaluation of CDCA3 expression in OSCC-derived cell lines. A) 
Quantification of CDCA3 mRNA expression in OSCC-derived cell lines by qRT-PCR 
analysis. Significant up-regulation of CDCA3 mRNA is seen in six OSCC-derived cell 
lines compared with the HNOKs (*p < 0.05, Mann-Whitney’s U test). Data are 
expressed as the means ± SEM of triplicate results. B) A representative Western blot 
of CDCA3 protein in OSCC-derived cell lines and HNOKs shows that CDCA3 protein 
expression is up-regulated in OSCC-derived cell lines compared with HNOKs. 
Densitometric CDCA3 protein data are normalized to α-tubulin protein levels. The 
values are expressed as a percentage of the HNOKs. 
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Figure 2 Evaluation of CDCA3 expression in normal oral tissues, OPLs, and 
primary OSCCs. A) qRT-PCR analysis shows that CDCA3 mRNA expression is 
up-regulated in 51 (74%) of 69 primary OSCCs compared with the matched normal 
oral tissues. The relative mRNA expression levels in the normal oral tissues and 
primary OSCCs range from 6.3 × 10-5 to 0.442 (median, 0.033) and 5.9 × 10-5 to 1.178 
(median, 0.083), respectively. Significantly higher CDCA3 mRNA expression is seen in 
primary OSCCs than matched normal oral tissues (**p < 0.001, Mann-Whitney’s U 
test). B) The status of CDCA3 protein expression in primary OSCCs and paired 
normal oral tissues from 95 patients and OPLs from 20 patients based on an IHC 
scoring system. The CDCA3 IHC scores of normal oral tissues, OPLs, and OSCCs 
range from 2.5 to 87.5 (median, 22.5), 2.5 to 50.0 (median, 15.0), and 2.5 to 225.0 
(median, 95.0), respectively. The CDCA3 protein expression level in OSCCs is 
significantly higher (**p < 0.001, Mann-Whitney’s U test) than in normal oral tissues 
and OPLs. No significant (p = not significant [n.s.]) difference in protein expression is 
seen between OPLs and normal oral tissues. Representative IHC results of CDCA3 in 
normal oral tissues (C), OPLs (D) and primary OSCCs (E) (×100 magnification. Scale 
bars, 50 µm.). A strong CDCA3 immunoreaction is seen in OSCCs, whereas normal 
oral tissues and OPLs show almost negative immunostaining. 
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Figure 3 mRNA and protein expression in shCDCA3-transfected cells using 
qRT-PCR and Western blot analyses. A, B) qRT-PCR shows that CDCA3 is 
down-regulated in shCDCA3-transfected cells compared with the mock-transfected 
cells (*p < 0.05, Mann-Whitney’s U test). Data are expressed as the means ± SEM of 
triplicate results. C, D) The densitometric CDCA3 protein levels in shCDCA3- and 
mock-transfected cells show that CDCA3 protein is markedly decreased in 
shCDCA3-transfected cells compared with mock-transfected cells (*p < 0.05, 
Mann-Whitney’s U test).  
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Figure 4 Proliferation of shCDCA3-transfected H1 (A) and Sa3 (B) cells. The 
shCDCA3-transfected H1 and Sa3 cells show a significant (*p < 0.05, Mann-Whitney’s 
U test) decrease in cellular growth compared with mock-transfected cells. The results 
are expressed as the means ± SEM of values from three assays. Representative 
Western blot data shows that CDCA3 proteins are markedly down-regulated in 
shCDCA3-transfected H1 (A) and Sa3 (B) cells. 
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Figure 5 Flow cytometric determination of DNA content in shCDCA3- and 
mock-transfected cells. A) Representative FACS analysis shows that the number of 
cells in the G1 phase is significantly (*p < 0.05, Mann-Whitney’s U test) increased in 
shCDCA3-transfected H1 and Sa3 cells. B) Western blot analysis of CDKIs (p21Cip1 
p27Kip1, p15INK4B, and p16INK4A), CDK4, CDK6, Cyclin D1, and Cyclin E shows 
up-regulation of p21Cip1, p27Kip1, p15INK4B, p16INK4A, CDK4, and Cyclin D1, and 
down-regulation of CDK6 and Cyclin E in the CDCA3 knockdown cells. 
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Figure 6 Quantification of CDKIs (p21Cip1, p27Kip1, p15INK4B, and p16INK4A), CDK4, 
CDK6, Cyclin D1, and Cyclin E protein expression in shCDCA3- and mock-transfected 
cells. A, B) Western blot analysis shows up-regulation of p21Cip1, p27Kip1, p15INK4B, 
p16INK4A, CDK4, and Cyclin D1, and down-regulation of CDK6 and Cyclin E in the 
CDCA3 knockdown cells. 
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Figure 7 Quantification of Wee1 mRNA expression in OSCC-derived cell lines by 
qRT-PCR analysis. Significant down-regulation of Wee1 mRNA is seen in six 
OSCC-derived cell lines compared with the HNOKs (*p < 0.05, Mann-Whitney’s U 
test). Data are expressed as the means ± SEM of triplicate results. 
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Figure 8 Quantification of Wee1 mRNA expression in shCDCA3- and 
mock-transfected cells by qRT-PCR analysis. Significant up-regulation of Wee1 mRNA 
is seen in shCDCA3-transfected H1 (A) and Sa3 (B) cells compared with the 
mock-transfected cells (*p < 0.05, Mann-Whitney’s U test). Data are expressed as the 
means ± SEM of triplicate results. 
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Table 1 Correlation between CDCA3 expression and clinical classification in OSCCs  
    Results of immunostaining   
Clinical 
classification  No. patients (%)  
  Total CDCA3 negative 
CDCA3 
positive p  value 
Age at surgery 
(years)     
  <60 23      9  (39)     14  (61)    ≧60, <70 22 11  (50)     11  (50) 0.852 
  ≧70 50 22  (44)     28  (56)  
Gender       Male 58 28  (48)     30  (52) 0.317   Female 37     14  (38)     23  (62) 
T-primary tumor       T1 6      3  (50)      3  (50) 
 0.020*   T2 56 30  (54)     26  (46)   T3 15      5  (33)     10  (67) 
  T4 18      4  (22)     14  (78) 
  T1+T2 62     33  (53)     29  (47)  0.015*   T3+T4 33      9  (27)     24  (73) 
N-regional lymph node      N (-) 56 25  (45) 31  (55) 0.919   N (+) 39     17  (44)     22  (56) 
Stage       I 6      3  (50)      3  (50) 
0.235   II 36     18  (50)     18  (50)   III 17      8  (47)      9  (53) 
  IV 36     13  (36)     23  (64) 
Histopathologic type       Well 60     26  (43)     34  (57) 
0.803   Moderately 31     14  (45)     17  (55) 
  Poorly 4      2  (50)      2  (50) 
Tumor site       Gingiva 28      9  (32)     19  (68) 
0.456   Tongue 51     25  (49)     26  (51)   Buccal mucosa 9      4  (44)      5  (56) 
  Oral floor 7      4  (57)      3  (43) 
*p < 0.05.  
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